Dr. Robin van Geel

In 2011, Robin obtained his Master of Science degree in Pharmacy at the University of Utrecht and started with his PhD project at the Netherlands Cancer Institute, supervised by prof. dr. J.H.M. Schellens and prof. dr. J.H. Beijnen. He developed multiple phase I and phase II clinical trials in which he studied new combinations of targeted anticancer agents, which specifically target certain ‘driver’ mutations in the DNA of cancer cells. During his PhD project, Robin also followed the clinical pharmacology education program of the Dutch Society of Clinical Pharmacology and Biopharmacy. In 2016, he obtained his PhD, received his degree in clinical pharmacology and started as a hospital pharmacist in training at the MUMC+. In 2020, he became staff member of the department of Clinical Pharmacy & Toxicology as Hospital Pharmacist and Clinical Pharmacologist at MUMC+, with focus on oncology, radiopharmacy and research. His research mainly focuses on the clinical pharmacology of targeted anticancer drugs.

Participations, projects and additional duties:

• DOAC SMI 2: Evaluating safety and efficacy of direct oral anticoagulants in patients receiving oral targeted anticancer treatments
• Osiboost 2: Using pharmacokinetics to improve cost-effectiveness of osimertinib treatment in non-small cell lung cancer